Ultragenyx Pharmaceutical
RARE
176 hedge funds and large institutions have $3.8B invested in Ultragenyx Pharmaceutical in 2018 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 46 increasing their positions, 59 reducing their positions, and 15 closing their positions.
516% more call options, than puts
Call options by funds: $40.4M | Put options by funds: $6.55M
133% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 15
11% more funds holding
Funds holding: 158 → 176 (+18)
1.08% more ownership
Funds ownership: 98.07% → 99.15% (+1.1%)
1% more capital invested
Capital invested by funds: $3.75B → $3.8B (+$48.1M)
22% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 59
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$61.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$51.2M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$23.3M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$22.2M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$21.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$66.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$23M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22.3M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$18.8M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$14.4M |
RARE Hedge Fund Activity: Q3 2018 in Review
176 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2018, worth a combined $3.8B — up 1.3% from $3.75B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new RARE positions and 15 closed out — a net gain of 20 holders — while 46 added to existing stakes and 59 trimmed.
The largest buyer was Capital International Investors, adding an estimated $61.4M. The largest seller was Wellington Management Group, cutting an estimated $66.3M.
- 176 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2018, up from 158 in Q2 2018.
- Funds reported $3.8B of Ultragenyx Pharmaceutical stock for Q3 2018, up 1.3% quarter-over-quarter.
- 35 funds opened new Ultragenyx Pharmaceutical positions in Q3 2018 and 15 closed out, a net change of +20 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2018 was Capital International Investors, an estimated $61.4M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2018 was Wellington Management Group, an estimated $66.3M sold.
Based on aggregated 13F filings for Q3 2018.